Literature DB >> 28130473

Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations.

Salvatore Spina1, Daniel R Schonhaut2, Bradley F Boeve2, William W Seeley2, Rik Ossenkoppele2, James P O'Neil2, Andreas Lazaris2, Howard J Rosen2, Adam L Boxer2, David C Perry2, Bruce L Miller2, Dennis W Dickson2, Joseph E Parisi2, William J Jagust2, Melissa E Murray2, Gil D Rabinovici2.   

Abstract

OBJECTIVE: To assess the efficacy of [18F]AV1451 PET in visualizing tau pathology in vivo in a patient with frontotemporal dementia (FTD) associated with the V337M microtubule-associated protein tau (MAPT) mutation.
METHODS: MAPT mutations are associated with the deposition of hyperphosphorylated tau protein in neurons and glia. The PET tracer [18F]AV1451 binds with high affinity to paired helical filaments tau that comprises neurofibrillary tangles in Alzheimer disease (AD), while postmortem studies suggest lower or absent binding to the tau filaments of the majority of non-AD tauopathies. We describe clinical, structural MRI, and [18F]AV1451 PET findings in a V337M MAPT mutation carrier affected by FTD and pathologic findings in his affected mother and in an unrelated V337M MAPT carrier also affected with FTD. The biochemical similarity between paired helical filament tau in AD and MAPT V337M predicts that the tau pathology associated with this mutation constitutes a compelling target for [18F]AV1451 imaging.
RESULTS: We found a strong association between topography and degree of [18F]AV1451 tracer retention in the proband and distribution of tau pathology in the brain of the proband's mother and the unrelated V337M mutation carrier. We also found a significant correlation between the degree of regional MRI brain atrophy and the extent of [18F]AV1451 binding in the proband and a strong association between the proband's clinical presentation and the extent of regional brain atrophy and tau accumulation as assessed by structural brain MRI and [18F]AV1451PET.
CONCLUSION: Our study supports the usefulness of [18F]AV1451 to characterize tau pathology in at least a subset of pathogenic MAPT mutations.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28130473      PMCID: PMC5344079          DOI: 10.1212/WNL.0000000000003636

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

1.  Classification of primary progressive aphasia and its variants.

Authors:  M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman
Journal:  Neurology       Date:  2011-02-16       Impact factor: 9.910

2.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

Authors:  David T Chien; Shadfar Bahri; A Katrin Szardenings; Joseph C Walsh; Fanrong Mu; Min-Ying Su; William R Shankle; Arkadij Elizarov; Hartmuth C Kolb
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

3.  [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease.

Authors:  Chun-Fang Xia; Janna Arteaga; Gang Chen; Umesh Gangadharmath; Luis F Gomez; Dhanalakshmi Kasi; Chung Lam; Qianwa Liang; Changhui Liu; Vani P Mocharla; Fanrong Mu; Anjana Sinha; Helen Su; A Katrin Szardenings; Joseph C Walsh; Eric Wang; Chul Yu; Wei Zhang; Tieming Zhao; Hartmuth C Kolb
Journal:  Alzheimers Dement       Date:  2013-02-12       Impact factor: 21.566

4.  [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration.

Authors:  Keith A Josephs; Jennifer L Whitwell; Pawel Tacik; Joseph R Duffy; Matthew L Senjem; Nirubol Tosakulwong; Clifford R Jack; Val Lowe; Dennis W Dickson; Melissa E Murray
Journal:  Acta Neuropathol       Date:  2016-09-19       Impact factor: 17.088

5.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

6.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

7.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

Authors:  M G Spillantini; J R Murrell; M Goedert; M R Farlow; A Klug; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

8.  18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.

Authors:  Ruben Smith; Andreas Puschmann; Michael Schöll; Tomas Ohlsson; John van Swieten; Michael Honer; Elisabet Englund; Oskar Hansson
Journal:  Brain       Date:  2016-06-29       Impact factor: 13.501

9.  Variation in longevity gene KLOTHO is associated with greater cortical volumes.

Authors:  Jennifer S Yokoyama; Virginia E Sturm; Luke W Bonham; Eric Klein; Konstantinos Arfanakis; Lei Yu; Giovanni Coppola; Joel H Kramer; David A Bennett; Bruce L Miller; Dena B Dubal
Journal:  Ann Clin Transl Neurol       Date:  2015-01-26       Impact factor: 5.430

10.  An autoradiographic evaluation of AV-1451 Tau PET in dementia.

Authors:  Val J Lowe; Geoffry Curran; Ping Fang; Amanda M Liesinger; Keith A Josephs; Joseph E Parisi; Kejal Kantarci; Bradley F Boeve; Mukesh K Pandey; Tyler Bruinsma; David S Knopman; David T Jones; Leonard Petrucelli; Casey N Cook; Neill R Graff-Radford; Dennis W Dickson; Ronald C Petersen; Clifford R Jack; Melissa E Murray
Journal:  Acta Neuropathol Commun       Date:  2016-06-13       Impact factor: 7.801

View more
  42 in total

1.  Tau Diagnostics and Clinical Studies.

Authors:  Illana Gozes; Günter Höglinger; James P Quinn; Nigel M Hooper; Kina Höglund
Journal:  J Mol Neurosci       Date:  2017-10       Impact factor: 3.444

2.  [18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window.

Authors:  Julien Lagarde; Pauline Olivieri; Fabien Caillé; Philippe Gervais; Jean-Claude Baron; Michel Bottlaender; Marie Sarazin
Journal:  J Neurol       Date:  2019-09-18       Impact factor: 4.849

Review 3.  Neuroimaging in Dementia.

Authors:  Adam M Staffaroni; Fanny M Elahi; Dana McDermott; Kacey Marton; Elissaios Karageorgiou; Simone Sacco; Matteo Paoletti; Eduardo Caverzasi; Christopher P Hess; Howard J Rosen; Michael D Geschwind
Journal:  Semin Neurol       Date:  2017-12-05       Impact factor: 3.420

Review 4.  FTD spectrum: Neuroimaging across the FTD spectrum.

Authors:  Jennifer L Whitwell
Journal:  Prog Mol Biol Transl Sci       Date:  2019-06-18       Impact factor: 3.622

Review 5.  Small-molecule PET Tracers for Imaging Proteinopathies.

Authors:  Chester A Mathis; Brian J Lopresti; Milos D Ikonomovic; William E Klunk
Journal:  Semin Nucl Med       Date:  2017-07-13       Impact factor: 4.446

Review 6.  Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress.

Authors:  Illana Gozes
Journal:  EPMA J       Date:  2017-09-04       Impact factor: 6.543

7.  Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET.

Authors:  Jochen Hammes; Isabel Leuwer; Gérard N Bischof; Alexander Drzezga; Thilo van Eimeren
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-12       Impact factor: 9.236

8.  18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.

Authors:  David N Soleimani-Meigooni; Leonardo Iaccarino; Renaud La Joie; Suzanne Baker; Viktoriya Bourakova; Adam L Boxer; Lauren Edwards; Rana Eser; Maria-Luisa Gorno-Tempini; William J Jagust; Mustafa Janabi; Joel H Kramer; Orit H Lesman-Segev; Taylor Mellinger; Bruce L Miller; Julie Pham; Howard J Rosen; Salvatore Spina; William W Seeley; Amelia Strom; Lea T Grinberg; Gil D Rabinovici
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

9.  Differences in gray and white matter 18F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias.

Authors:  Hye Joo Son; Jungsu S Oh; Jee Hoon Roh; Sang Won Seo; Minyoung Oh; Sang Ju Lee; Seung Jun Oh; Jae Seung Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-14       Impact factor: 9.236

10.  In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease.

Authors:  Gregory S Day; Brian A Gordon; Richard J Perrin; Nigel J Cairns; Helen Beaumont; Katherine Schwetye; Cole Ferguson; Namita Sinha; Robert Bucelli; Erik S Musiek; Nupur Ghoshal; Maria R Ponisio; Benjamin Vincent; Shruti Mishra; Kelley Jackson; John C Morris; Tammie L S Benzinger; Beau M Ances
Journal:  Neurology       Date:  2018-02-07       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.